Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-CLS-628 for autosomal dominant polycystic kidney disease
2024-517143-31-00Phase 2Authorised
- Sponsor
- Calico Life Sciences
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing ABBV-CLS-628 with Placebo for ABBV-CLS-628 (2 arms). Primary endpoint: Cumulative rate of change from baseline in total kidney volume by MRI at Week 96. Planned start Jul 2025; status: authorised.
02
Drugs
ABBV-CLS-628
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2024-517143-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517143-31-00.